15236
N,O-Bis(trimethylsilyl)carbamate
≥98.0% (T)
Synonym(s):
BSC, Trimethylsilyl N-(trimethylsilyl)carbamate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
(CH3)3SiNHCO2Si(CH3)3
CAS Number:
Molecular Weight:
205.40
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
252-520-4
Beilstein/REAXYS Number:
2043399
MDL number:
Assay:
≥98.0% (T)
Form:
solid
Quality Level
assay
≥98.0% (T)
form
solid
mp
77-83 °C
functional group
amine
SMILES string
C[Si](C)(C)NC(=O)O[Si](C)(C)C
InChI
1S/C7H19NO2Si2/c1-11(2,3)8-7(9)10-12(4,5)6/h1-6H3,(H,8,9)
InChI key
DGIJAZGPLFOQJE-UHFFFAOYSA-N
Other Notes
Extremely suitable reagent for the silylation of alcohols, phenols and carboxylic acids. The only by-products are CO2 and NH3; Silyloxycarbonylation of amines; Acylisocyanates from carboxylic acid chlorides
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs
Gregor Vlacic et al.
Cells, 8(9) (2019-09-19)
Malignant pleural mesothelioma (MPM) is a devastating malignancy with limited therapeutic options. Fibroblast growth factor receptors (FGFR) and their ligands were shown to contribute to MPM aggressiveness and it was suggested that subgroups of MPM patients could benefit from FGFR-targeted
Ronak Saluja et al.
Journal of oncology practice, 14(5), e280-e294 (2018-03-31)
The purpose of this study was to determine if clinical benefits of novel anticancer drugs, measured by the ASCO Value Framework and European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale, have increased over time in parallel with
Stefania De Lorenzo et al.
Scientific reports, 8(1), 9997-9997 (2018-07-04)
There is a relative lack of evidence about systemic treatments in patients with hepatocellular carcinoma (HCC) and moderate liver dysfunction (Child-Pugh B). In this multicenter study we retrospectively analyzed data from Child-Pugh B-HCC patients naïve to systemic therapies, treated with
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 15236-10G | 04061832098241 |